Veracyte (VCYT) Revenue (2012 - 2026)

Veracyte (VCYT) has 15 years of Revenue data on file, last reported at $139.1 million in Q1 2026.

• Quarterly Revenue rose 21.49% year-over-year to $139.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $541.7 million (up 16.91% YoY) and the FY2025 annual result came in at $517.1 million, up 16.01% from the prior year.
• Revenue declined to $139.1 million in Q1 2026 per VCYT's latest filing, from $140.6 million in the prior quarter.
• The five-year high for Revenue was $140.6 million in Q4 2025, with the low at $67.8 million in Q1 2022.
• Average Revenue over 5 years is $103.5 million, with a median of $98.2 million recorded in 2023.
• Year-over-year, Revenue soared 84.68% in 2022 and increased 13.75% in 2025.
• Veracyte's Revenue stood at $80.3 million in 2022, then gained by 22.29% to $98.2 million in 2023, then climbed by 20.81% to $118.6 million in 2024, then rose by 18.55% to $140.6 million in 2025, then slipped by 1.11% to $139.1 million in 2026.
• Business Quant data shows VCYT's Revenue at $139.1 million in Q1 2026, $140.6 million in Q4 2025, and $131.9 million in Q3 2025.